Is Eli Lilly stock expected to go up?

Yes, all signs point to a great year for Eli Lilly stock in 2026 and beyond.

Is Eli Lilly stock a good investment?

Pharmaceutical stocks are always a little risky, but if LLY keeps up the momentum it's building, it could become a fantastic investment for people brave enough to jump in.

What is the stock price prediction for Eli Lilly in 2026?

Wall Street puts the average price target for Eli Lilly in 2026 at $1,218.72.

Eli Lilly (LLY) Stock Predictions for 2026 and Beyond

Eli Lilly (LLY) Stock Predictions: What Investors Should Expect in 2026 and Beyond

By Kristi Waterworth – Updated Jun 24, 2026 at 2:39 PM EST | Fact-checked by Parker Hicks

Key Points

LLY stock's 2026 target is $1,218.72, above its current price, showing strong analyst optimism.
CoinCodex predicts a 2030 LLY price of $4,003.07, a potential 38% annual growth.
Acquisition of 4E Therapeutics may broaden LLY’s portfolio, reducing reliance on GLP-1 drugs.

Knowing what's in store for a stock can help you make better buying decisions, for example, a solid LLY stock forecast will help you know if the company's share prices align with your own investing time horizon. Eli Lilly, the maker of blockbuster GLP-1 drugs Zepbound, Mounjaro, and Foundayo, is a foundational choice for pharma investors, especially as it has recently acquired non-opioid pain treatment developer 4E Therapeutics. Read on to learn more about the present and future of this stock.

Loading paragraph...

Eli Lilly (LLY) Forecast

The Eli Lilly story has been big news for the last couple of years as GLP-1s exploded onto the scene. Everyone and their uncle was getting on these drugs to help them shed stubborn pounds, and to improve a huge range of diseases, including diabetes and obesity. This was already enough to make the company a stock market darling, but recent acquisitions of non-opioid pain treatment company 4E Therapeutics on June 16, 2026 has helped the company to diversify its short-term pipeline. This could be the beginning of a promising future for Eli Lilly, even as some pharmaceutical stocks are struggling to maintain their COVID-era momentum.

Loading paragraph...

NYSE: LLY

Eli Lilly

Today's Change

(-0.52%) $-6.23

Current Price

$1,185.71

Key Data Points

Market Cap

$1.1T

Day's Range

$1161.20 - $1196.80

52wk Range

$625.90 - $1249.45

Volume

2.9M

Avg Vol

3.1M

Gross Margin

83.40%

Dividend Yield

0.54%

Loading company_card...

2026 forecast

Analysts believe that LLY is a stock that will do well this year. Wall Street has given it an average price target of $1,218.72, significantly higher than its $1,098 price tag at the close of the market on June 18, 2026. In fact of 31 recommendations in June, six analysts give it a Strong Buy, 18 more give it a Buy, and 5 give it a Hold. The experts are kind of into it.

Even CoinCodex, a technical trading website that is often not very near-term optimistic for individual stocks, sees an average annualized price of $1,253.57 for 2026. It could be a good year to be an LLY investor.

2030 forecast

There's a lot of hope for the future of LLY, and the company does seem to be actively trying to build out a business model that ensures that will come to pass. CoinCodex predicts an average annualized price of $4,003.07 in 2030, or about a 38% CAGR over four years.

By comparison, a more conservative CAGR of 8 - 12% would put the stock price in 2030 at about $1,493 - $1,727. Even at this more conservative rate, someone who bought LLY at around $1,100 would be doing pretty well.

Loading paragraph...

Eli Lilly's Highlights and Risks

Being an Eli Lilly stock investor does mean accepting that pharmaceutical companies are high risk investments, especially if they are kind of a one-trick pony. LLY is trying hard to offset this, but it still remains vulnerable to risks that include:

An overall shift in the pharma landscape. New competitors in the GLP-1 space would definitely put the love of LLY at risk for investors. Right now, LLY is the leader in this area, but it doesn't take a lot to be overcome by a company with a more effective product, one that is less expensive, or one that is easier to administer. Just like its own oral GLP-1 has kind of put it out in front, another company could come in and do the same with something slightly different.
Production issues or regulatory changes. From time to time, production issues or changes in the regulatory environment can create big headaches for pharmaceutical companies. Maybe they suddenly can't get a specific compound they need for their popular Zepbound drug, creating a production bottleneck. Or worse yet, something happens to users of the drug, and the FDA is suddenly investigating. These are unforeseeable, but very real, risks in this space.

However, LLY is working to create new, sustainable income streams through its recent acquisition of 4E Therapeutics. This comes with a drug in the pipeline that is wholly different from its flagship brands, but that could become an additional big name in medicine. So many people can't or won't accept opioid pain medications after the opioid crisis. If this drug could solve that problem and help people who have chronic pain, it would be a double win for the company and give it yet another groundbreaking medication for its portfolio.

Eli Lilly (LLY) Stock Prediction FAQs

Loading faq...

About the Author

Kristi Waterworth has been a contributing real estate and financial expert at The Motley Fool, covering real estate, investing, and personal finance topics, since 2020. Kristi has been interviewed by various TV media outlets and podcasts for her real estate investing expertise – from residential real estate to digital real estate and everything in between. Kristi’s journalist career spans over 25 years, and she has written about real estate investing, homeownership, and home construction specifically for the last decade. She was also previously a licensed Realtor and general building contractor before the Great Recession and housing market collapse. She holds a bachelor’s degree in American history from Columbia College in Missouri.

TMFMaldivesBlue

@MaldivesBlues

Kristi Waterworth has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly. The Motley Fool has a disclosure policy.

Eli Lilly (LLY) Stock Predictions: What Investors Should Expect in 2026 and Beyond

Key Points

Eli Lilly (LLY) Forecast